Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).

Ou YamaguchiKeita MoriSaori TakataKazuhiko ShibataKenichi ChikamoriNozomu KimuraYoshiaki NagaiTaku NakagawaSatoshi IgawaTaishi HaradaHiroshige YoshiokaHisashi TanakaHitomi NogawaToshihiro ShiozawaToshihiro ShiozawaKosuke TsujiKunihiko KobayashiKyoichi Kaira

Published in: Thoracic cancer (2023)

Extended ICI treatment after chemoimmunotherapy and maintenance therapy enhanced the efficacy of second-line RD treatment in patients with advanced NSCLC.

Keyphrases

small cell lung cancer
stem cells
radiation therapy
rectal cancer
cell therapy
locally advanced
tyrosine kinase